Fosun Pharma (02196): XH-S004 tablets have initiated Phase II clinical trials for treating non-cystic fibrosis bronchiectasis within China.

The Zhixin Finance and Economics APP reports that Fosun Pharma (02196) announced that recently, its controlling subsidiary Zhejiang Xinghaopengbo Pharmaceutical Co., Ltd. has initiated Phase II clinical trials in China (excluding the regions of Hong Kong, Macau, and Taiwan) for XH-S004 tablets (application for registration classification: chemical medicine class 1; hereinafter referred to as "XH-S004") used in the treatment of non-cystic fibrosis bronchiectasis.